Abstract: Provided are an analog compound of an oligopeptide AQTGTGKT, which exhibits an excellent anticancer effect and is stably present in human blood, a pharmaceutical composition including the same as an active ingredient, and a preparation method thereof, wherein the analog compound advantageously exhibits an excellent effect of suppressing the proliferation of cancer cells, has less immune responses, and easily penetrates into tissue due to smaller molecular weights of oligopeptide preparations than those of antibodies, therefore it can be used as a useful anticancer agent for treating cancer.

Abstract: The present invention relates to a novel oligopeptide, and a pharmaceutical composition for preventing or treating cancer, comprising same as an active ingredient. The oligopeptide of the present invention has an advantage in that the molecular weight thereof is less than that of an antibody, and thus the risk of an immune response is low, and it has better tissue permeability. The oligopeptide can exhibit the effect of inhibiting the proliferation of malignant tumors by selectively acting on cancer cells or cancer tissue.

Abstract: Provided is a pharmaceutical composition for preventing or treating cancer, containing, as an active ingredient, an oligopeptide usable in treating cancer. Since an oligopeptide of the presently claimed subject matter has a molecular weight lower than those of antibodies, there are advantages for less concern of an immune response and easily penetrating into tissues, and selectively acting on cancer cells or cancer tissues.

Abstract: Provided are a polypeptide having the activity of inhibiting autophagy in a cell, a composition for inhibiting autophagy in a cell, and particularly in a tumor cell, containing the polypeptide as an active ingredient, and a pharmaceutical composition containing the polypeptide, and more specifically, a composition for inhibiting autophagy in a cell containing a polypeptide inhibiting the control mechanism of autophagy as an active ingredient, and a pharmaceutical composition for preventing or treating a neoplastic disease or for inhibiting resistance to anticancer agents, containing the polypeptide.

Abstract: Provided are a polypeptide having the activity of inhibiting autophagy in a cell, a composition for inhibiting autophagy in a cell, and particularly in a tumor cell, containing the polypeptide as an active ingredient, and a pharmaceutical composition containing the polypeptide, and more specifically, a composition for inhibiting autophagy in a cell containing a polypeptide inhibiting the control mechanism of autophagy as an active ingredient, and a pharmaceutical composition for preventing or treating a neoplastic disease or for inhibiting resistance to anticancer agents, containing the polypeptide.

Abstract: Provided are a polypeptide having the activity of inhibiting autophagy in a cell, a composition for inhibiting autophagy in a cell, and particularly in a tumor cell, containing the polypeptide as an active ingredient, and a pharmaceutical composition containing the polypeptide, and more specifically, a composition for inhibiting autophagy in a cell containing a polypeptide inhibiting the control mechanism of autophagy as an active ingredient, and a pharmaceutical composition for preventing or treating a neoplastic disease or for inhibiting resistance to anticancer agents, containing the polypeptide.

Abstract: The present invention relates to a controlled-release formulation comprising cilostazol and a method for preparing said formulation. The inventive controlled-release formulation comprising cilostazol or a pharmaceutically acceptable salt thereof, a solubilizing agent, a swelling agent, a swell-controlling agent and a gas generating material has advantages in that it maintains a constant cilostazol level in the blood through a slow release while it resides in the stomach and intestines over a long period of time, thereby increasing the absorption of cilostazol in the small intestine, the major absorption site of cilostazol, as well as minimizing adverse effects caused by rapid release and making it easy for a patient to take the drug.